LianBio (NASDAQ:LIAN) Shares Down 1.6%

LianBio (NASDAQ:LIAN)’s share price fell 1.6% on Thursday . The company traded as low as $0.29 and last traded at $0.31. 263,256 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 1,037,083 shares. The stock had previously closed at $0.32.

LianBio Stock Performance

The firm’s 50-day simple moving average is $1.23 and its 200-day simple moving average is $3.17. The company has a market capitalization of $33.50 million, a price-to-earnings ratio of -0.38 and a beta of 0.23.

LianBio Dividend Announcement

The company also recently declared a — dividend, which was paid on Thursday, March 14th. Shareholders of record on Tuesday, February 27th were issued a $4.80 dividend. The ex-dividend date of this dividend was Friday, March 15th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. TD Asset Management Inc boosted its stake in LianBio by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 357,038 shares of the company’s stock valued at $532,000 after buying an additional 178,519 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of LianBio in the 3rd quarter valued at $196,000. Acadian Asset Management LLC grew its holdings in shares of LianBio by 27.3% in the 3rd quarter. Acadian Asset Management LLC now owns 181,144 shares of the company’s stock worth $268,000 after purchasing an additional 38,808 shares during the last quarter. 22NW LP increased its position in shares of LianBio by 1,466.1% during the 3rd quarter. 22NW LP now owns 2,211,678 shares of the company’s stock worth $3,295,000 after purchasing an additional 2,070,455 shares in the last quarter. Finally, Axxcess Wealth Management LLC acquired a new stake in shares of LianBio during the 3rd quarter worth about $25,000. 74.85% of the stock is owned by institutional investors.

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.